胸腔镜肺段切除与肺叶切除治疗非小细胞肺癌的手术及术后特征与结局比较:意大利VATS组注册研究的倾向性评分匹配分析
该研究基于意大利VATS组注册数据,纳入2014年1月至2019年7月共7487例接受胸腔镜肺叶切除(7269例)或肺段切除(218例)的非小细胞肺癌患者,经倾向性评分匹配后分析349例肺叶切除与208例肺段切除。结果显示两组在中转开胸率、30天死亡率、总体并发症及延长漏气方面无显著差异,肺叶切除组切除淋巴结数量更多。肺段切除在术后并发症和死亡率方面与肺叶切除相当,可视为安全术式。
要点
- 倾向性匹配后肺段切除与肺叶切除的30天死亡率、总体并发症和中转开胸率无显著差异。
- 肺叶切除组切除淋巴结数量多于肺段切除组(中位11 vs 8,P=0.006)。
- 肺段切除可视为安全的术式,术后并发症和死亡率与胸腔镜肺叶切除相当。
核心结论
- 肺段切除在术后并发症和死亡率方面与胸腔镜肺叶切除无显著差异,可视为安全术式。
研究设计与样本
- 回顾性队列研究,基于意大利VATS组注册数据,纳入2014年1月至2019年7月共7487例患者(肺叶切除7269例,肺段切除218例),经倾向性评分匹配后分析349例肺叶切除与208例肺段切除。
主要发现
- 中转开胸率两组无统计学差异(肺叶切除27例8% vs 肺段切除7例3%,P=0.1)。
- 肺叶切除组切除淋巴结数量多于肺段切除组(中位11 vs 8,P=0.006)。
- 30天死亡率(1.4%,5例 vs 0.9%,2例)、总体并发症(18%,62例 vs 14%,29例)和延长漏气(31例9% vs 12例6%)无显著差异。
- 引流中位时间(3.2天,P=1)和总住院中位时间(6.4天,P=0.1)两组无统计学差异。
- 在肺段切除与对应肺叶切除的比较中,右上肺叶切除较右上肺段切除淋巴结切除数量更高(P=0.027),中转开胸率及术后并发症和死亡率无统计学差异。
临床怎么用
- 对于适合解剖性肺段切除的非小细胞肺癌患者,胸腔镜肺段切除可作为安全的术式选择,术后并发症和死亡率与肺叶切除相当。
- 临床决策时需注意肺段切除获取的淋巴结数量可能少于肺叶切除,应确保足够的淋巴结采样或清扫以准确分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Only few studies compared the surgical morbidity and mortality of thoracoscopic segmentectomy versus lobectomy for non-small-cell lung cancer, in particular, by relating the segmental resections with the corresponding anatomical lobes. METHODS: We enrolled a total of 7487 patients who underwent VATS lobectomy (7269) or segmentectomy (218) from January 2014 to July 2019. A propensity score matching approach was used to account for potential confounding factors between the 2 groups. After matching, 349 lobectomies and 208 segmentectomies were included in the analysis. We analysed the operative and postoperative outcomes of video-assisted anatomical segmentectomy compared with video-assisted lobectomy and, in details, the results of segmentectomy with its corresponding lobectomy in a large cohort of patients from the Italian VATS Group Registry. RESULTS: The overall conversion rate to thoracotomy was not statistically different between the groups (27 patients 8% vs 7 patients 3%, P = 0.1). The lobectomy group had a greater number of resected lymph nodes (median 11 vs 8, P = 0.006). No significant differences were detected in 30-day mortality (1.4%, 5 patients vs 0.9%, 2 patients), overall complications (18%, 62 patients vs 14%, 29 patients) and prolonged air leakage (31 patients, 9% vs 12 patients, 6%) between lobectomy and segmentectomy, respectively. No statistical differences were found regarding the median duration of drainage (3.2 days, P = 1) and the overall median length of hospital stay (6.4 days, P = 0.1) between the 2 groups. In the context of segmentectomy versus corresponding lobectomy, the right upper lobectomy compared with right upper segmentectomy showed a higher number of resected lymph nodes (P = 0.027). No statistical differences were reported in terms of conversion rate and postoperative complication and mortality. CONCLUSIONS: Segmentectomy could be considered a safe procedure without significant differences compared to thoracoscopic lobectomy in terms of postoperative morbidity and mortality.
引用
- Dell'Amore A, Lomangino I, Cannone G, et al. Comparison of operative and postoperative characteristics and outcomes between thoracoscopic segmentectomy and lobectomy for non-small-cell lung cancer: a propensity score matching study from the Italian VATS Group Registry. Eur J Cardiothorac Surg. 2022. PMID: 34643695. doi:10.1093/ejcts/ezab430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。